Furthermore, the use of Fresolimumab, a high-affinity neutralizing antibody that targets TGF-β isoforms, has also been explored in patients with FSGS [44] but had no benefit on partial or complete disease remission, though a trend to stabilized eGFR in the Fresolimumab group was described. Here, TGFB1 is linked to focal segmental glomerulosclerosis.